On Mar. 1, 2022, the CDC reported that Two doses of Pfizer-BioNTech vaccine protect against COVID-19ﾖassociated emergency department and urgent care encounters among children and adolescents.

However, vaccine effectiveness was lower during Omicron predominance and decreased with time since vaccination; a booster dose restored VE to 81% among adolescents aged 16ﾖ17 years. Overall, 2-dose VE against COVID-19ﾖassociated hospitalization was 73%ﾖ94%.